MET and diffuse large B-cell lymphoma: Moreover, in an in vivo xenograft, the combination of HDAC6 and MET inhibitors (like ricolinostat and crizotinib, respectively) had a potent anti-tumor activity, suggesting its use as “a promising therapeutic strategy for DLBCL”.